Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
Status:
Completed
Trial end date:
2020-11-18
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation study to evaluate the safety and efficacy of
intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in
situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety,
tolerability and efficacy of various doses of STP705 administered as Intralesional injection
in subjects with isSCC.
Goals:
- To determine the safe and effective recommended dose of STP705 for the treatment of
isSCC.
- Analysis of biomarkers common to isSCC formation pathway including TGF-β1 and COX-2.